Published in Oncoimmunology on July 25, 2016
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
TSC2 mediates cellular energy response to control cell growth and survival. Cell (2003) 20.21
AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature (2009) 10.59
AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol (2012) 10.42
Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol (2008) 9.25
Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol (2005) 6.05
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med (2007) 5.65
Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med (2011) 5.54
Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol (2005) 4.47
The JAK-STAT pathway at twenty. Immunity (2012) 4.41
Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and bacterial lipopolysaccharide. J Exp Med (1993) 4.06
Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol (2010) 3.86
Metformin in breast cancer: time for action. J Clin Oncol (2009) 3.81
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med (2005) 3.80
IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol (2003) 3.69
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res (2010) 3.53
Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol (2002) 2.73
The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci U S A (2009) 2.55
PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci U S A (2003) 2.40
Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene (2007) 2.27
The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology (2013) 2.14
Inhibition of fatty acid and cholesterol synthesis by stimulation of AMP-activated protein kinase. FASEB J (1995) 1.94
Degradation of AMPK by a cancer-specific ubiquitin ligase. Cell (2015) 1.91
PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res (2011) 1.87
Metformin activates AMP kinase through inhibition of AMP deaminase. J Biol Chem (2010) 1.76
Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci (2014) 1.69
Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab (2013) 1.68
Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat (2010) 1.65
AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells. Cancer Res (2012) 1.52
5-aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis. J Immunol (2005) 1.49
Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy. Cancer Immunol Immunother (2011) 1.47
Inhibition of inducible nitric-oxide synthase by activators of AMP-activated protein kinase: a new mechanism of action of insulin-sensitizing drugs. J Biol Chem (2004) 1.38
Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J Immunother Cancer (2013) 1.35
Signalling events involved in interferon-gamma-inducible macrophage nitric oxide generation. Immunology (2003) 1.19
Signaling pathways involved in MDSC regulation. Biochim Biophys Acta (2014) 1.12
Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator. J Biol Chem (2011) 1.10
Development of novel adenosine monophosphate-activated protein kinase activators. J Med Chem (2010) 1.04
AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis. Cancer Res (2014) 1.04
JAK2/STAT3, not ERK1/2, mediates interleukin-6-induced activation of inducible nitric-oxide synthase and decrease in contractility of adult ventricular myocytes. J Biol Chem (2003) 1.02
Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy. Clin Cancer Res (2006) 1.00
Repurposing metformin for cancer treatment: current clinical studies. Oncotarget (2016) 0.95
Activation of AMP-activated protein kinase revealed by hydrogen/deuterium exchange mass spectrometry. Structure (2013) 0.91
Augmented AMPK activity inhibits cell migration by phosphorylating the novel substrate Pdlim5. Nat Commun (2015) 0.87
Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment. Cancer Res (2016) 0.83
A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth. J Clin Endocrinol Metab (2015) 0.80
Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small-cell lung cancer. Clin Exp Immunol (2015) 0.80